← Back to Home

A New Clue for an Old Blood Pressure Drug: AI Imaging Analysis Points to Losartan Activating Brown Fat

Starting with cancer follow-up data from more than 100,000 people, researchers identified an association between medication use and brown fat, then tested it in cells and mice. This path toward repurposing an existing drug has preliminary support, but has not yet been shown to improve metabolism in humans.

By SURL BioNews

Human fat does more than store energy; it can also expend energy to generate heat. How to safely activate this type of brown fat has long been a challenge in metabolic research. Now, the common blood pressure drug losartan has emerged as a new research candidate: a study published in *Nature* on October 14 found clues in extensive clinical imaging and medical records, and observed effects that enhanced brown fat activity in cells and mice.

A team from Rockefeller University and Memorial Sloan Kettering Cancer Center analyzed data from 101,243 patients, including positron emission tomography/computed tomography (PET/CT) scans used for cancer follow-up and more than 500 diagnostic codes. These records, originally collected during cancer care, offered a window into the relationship between brown fat and other diseases; however, they were not clinical trials designed to test metabolic therapies.

Machine learning was used to turn images into comparable measurements. The team semiautomatically quantified activity throughout the body and in six anatomical regions in 8,709 patients whose scans showed brown fat. The analysis showed that brown fat location also mattered: greater activity in the underarm region was particularly associated with a lower prevalence of hypertension. This is a statistical association and cannot yet be interpreted to mean that increasing underarm brown fat can lower blood pressure.

The researchers then turned to medication records and found that people taking angiotensin receptor blockers were more likely to have brown fat visible on imaging, prompting them to select one of these drugs, losartan, for experiments. According to Rockefeller University, cultured brown fat cells showed increased metabolic activity after treatment; mice given the drug also increased their energy expenditure, but their body weight did not change. Increasing energy expenditure and achieving weight loss remain two outcomes that need to be validated separately.

The disease associations were not uniformly favorable either. The team found that people with visible brown fat had fewer diagnoses of some anxiety and depressive disorders, but more diagnoses of certain skin diseases. The university also mentioned a potentially adverse association with osteoporosis; the paper, however, more cautiously noted that the difference in osteoporosis prevalence was not statistically significant after adjustment. These signals suggest that evaluating the value of activating brown fat requires looking beyond energy expenditure alone.

The imaging measurements themselves also have limits: PET/CT primarily captures glucose uptake, which does not necessarily equate to how much heat brown fat actually generates. Moreover, because the data came from a cancer center, residual bias remains difficult to rule out even though the analysis adjusted for multiple confounding factors, and the findings cannot be directly generalized to the broader population.

The advance in this study lies in taking a drug association found in clinical data and developing it into a candidate approach that can be tested experimentally. Whether losartan can safely and sustainably activate brown fat in humans, and whether this is sufficient to improve blood glucose, body weight, or cardiovascular health, still requires dedicated human intervention studies; the current evidence is not yet sufficient to establish a new metabolic treatment use.

References

  1. Nature
  2. The Rockefeller University